Pharma: Page 2

  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Amgen to lay off 350 Horizon staffers weeks after closing $28B deal

    The latest round of cuts brings the company’s total announced workforce reductions this year to more than 1,000.

    By Kristin Jensen • Oct. 25, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis delays FDA filing for in-demand radiopharma drug

    Mixed survival data from a study of Pluvicto in earlier prostate cancer sparked the slower regulatory timeline.

    By • Oct. 24, 2023
  • Single strand ribonucleic acid, RNA research Explore the Trendline➔
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Ashley McEvoy, J&J's worldwide chairman of Medical Devices
    Image attribution tooltip
    Permission granted by Johnson & Johnson
    Image attribution tooltip

    J&J medtech head Ashley McEvoy to step down

    McEvoy is leaving the company after 27 years to pursue other opportunities. Tim Schmid will now lead the MedTech business.

    By Elise Reuter • Updated Oct. 24, 2023
  • Medicine doctor touching tablet with digital healthcare and network connection and hologram modern virtual screen interface icons, Medical technology and futuristic concept.
    Image attribution tooltip

    shutterstock.com/SOMKID THONGDEE

    Image attribution tooltip
    Sponsored by Target RWE

    Leveraging real-world evidence with analytics: 3 essential components to capture a 360-degree view of your patient population

    Three essential components to create impactful real-world evidence with a 360-degree patient journey.

    By Ewa Kleczyk, PhD, SVP, Commercial Analytics & Data Curation • Oct. 23, 2023
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck allies with Daiichi Sankyo in major bet on antibody cancer drugs

    The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.

    By • Oct. 20, 2023
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J again bumps forecasts on strong immune drug sales

    Tuesday’s earnings were the first since J&J officially split off its consumer drug business, now the publicly traded company Kenvue.

    By • Oct. 17, 2023
  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2024

    A few key meetings remain this year, like AHA and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

    By • Oct. 16, 2023
  • A computer screen shows the Pfizer logo and stock price at the New York Stock Exchange
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Pfizer to cut costs, lay off staff on waning demand for COVID products

    Sales of Pfizer’s pill Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral drug has been delayed. Shares rose Monday on the reset guidance.

    By • Updated Oct. 16, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    Pfizer wins FDA approval for its $7B colitis drug

    Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.

    By • Oct. 13, 2023
  • A castor bean tick on a leaf
    Image attribution tooltip
    Erik Karits via Getty Images
    Image attribution tooltip

    Research group says FDA found no misconduct in Pfizer Lyme vaccine trial it helped run

    Earlier this year Pfizer removed thousands of participants from a study of its Lyme disease shot over concerns the group, Care Access, wasn't meeting clinical practice standards.

    By • Oct. 12, 2023
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer opens California plant to make cell therapies

    The pharma plans for the new Berkeley facility to produce clinical, and potentially commercial, supplies of a Parkinson’s disease cell therapy being tested by its subsidiary BlueRock. 

    By • Oct. 10, 2023
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK partners with Chinese pharma to expand Shingrix sales

    The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

    By • Oct. 9, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis sales numbers show steady demand for new eye drug, despite safety worries

    The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.

    By Kristin Jensen • Oct. 5, 2023
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna claims positive results in early study for combo COVID, flu shot

    The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.

    By • Oct. 4, 2023
  • A building with logo of drugmaker Eli Lilly.
    Image attribution tooltip
    Eli Lilly & Co.
    Image attribution tooltip

    Lilly names new diabetes and obesity chief as Mounjaro sales take off

    Company veteran Mike Mason, who took leadership of the division four years ago, is retiring and will be replaced by immunology head Patrik Jonsson.

    By • Oct. 4, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Sandoz spins out of Novartis as standalone generic drugmaker

    The spinoff, now complete, is a major step in CEO Vas Narasimhan’s plan to refocus Novartis more tightly around novel prescription drugs and new technologies.

    By Kristin Jensen • Oct. 4, 2023
  • E. coli bacteria growing in a petri dish
    Image attribution tooltip
    Sproetniek via Getty Images
    Image attribution tooltip

    J&J, retreating from infectious disease, partners with Sanofi on E. coli vaccine

    The French vaccine giant will pay J&J $175 million to share rights to the experimental inoculation, which is currently in Phase 3 testing.

    By Kristin Jensen • Oct. 3, 2023
  • Prostate cancer cells, 3D illustration. Prostate cancer awareness image
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout

    Point Biopharma is one of the most advanced in a group of emerging biotechs working on radioligand therapies for cancer.

    By • Oct. 3, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis’ closely watched rare disease drug scores in kidney disorder

    Called iptacopan, the experimental medicine has now scored positive results in three late-stage clinical trials, the latest in an uncommon kidney disorder known as IgA nephropathy.

    By • Oct. 2, 2023
  • Female Doctor researching in laptop
    Image attribution tooltip
    Edwin Tan via Getty Images
    Image attribution tooltip
    Sponsored by SAS

    Ready for open source in life sciences? Your pharma analytics journey might be

    It’s time to adopt open-source technology – but not without security, compliance and guardrails.

    By Mark Lambrecht, Senior Director, Health and Life Sciences Practice • Oct. 2, 2023
  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip

    Novo Nordisk, Evotec partner in metabolic disease drug discovery pact

    Hunting for more metabolic disease drugs, Novo plans to work with Evotec to shape early academic research into new development programs.

    By • Sept. 26, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis radiopharmaceutical drug succeeds in first-line gut cancer study

    Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

    By • Sept. 25, 2023
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai’s Alzheimer’s drug Leqembi approved in Japan

    Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

    By • Sept. 25, 2023
  • Doctors working in lab
    Image attribution tooltip

    Anthony Musmanno

    Image attribution tooltip
    Sponsored by Viatris

    Driving innovation to benefit people living with MS

    A holistic approach to R&D is key to support MS patients throughout their treatment journey.

    By Pat Vallano, Ph.D., Head of Innovative Programs, R&D, Viatris • Sept. 25, 2023
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors

    Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

    By • Sept. 22, 2023